Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia.

Gene

The Granulocyte Research Laboratory, Department of Hematology, National University Hospital, University of Copenhagen, Copenhagen, Denmark; Section of Haematology-Oncology, Department of Clinical Genetics, National University Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address:

Published: June 2017

t(8;21) acute myeloid leukemia (AML) is characterized by a translocation between chromosomes 8 and 21 and formation of a distinctive RUNX1-RUNX1T1 fusion transcript. This translocation places RUNX1T1 under control of the RUNX1 promoter leading to a pronounced upregulation of RUNX1T1 transcripts in t(8;21) AML, compared to normal hematopoietic cells. We investigated the role of highly-upregulated RUNX1T1 under the hypothesis that it acts as competing endogenous RNA (ceRNA) titrating microRNAs (miRNAs) away from their target transcripts and thus contributes to AML formation. Using publicly available t(8;21) AML RNA-Seq and miRNA-Seq data available from The Cancer Genome Atlas (TCGA) project, we obtained a network consisting of 605 genes that may act as ceRNAs competing for miRNAs with the suggested RUNX1T1 miRNA sponge. Among the 605 ceRNA candidates, 121 have previously been implied in cancer development. Players in the integrin, cadherin, and Wnt signaling pathways affected by the RUNX1T1 sponge were overrepresented. Finally, among a set of 21 high interest RUNX1T1 ceRNAs we found multiple genes that have previously been linked to AML formation. In conclusion, our study offers a novel look at the role of the RUNX1-RUNX1T1 fusion transcript in t(8;21) AML beyond previously investigated genetic and epigenetic aberrations.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2017.03.015DOI Listing

Publication Analysis

Top Keywords

t821 aml
12
mirna sponge
8
t821 acute
8
acute myeloid
8
myeloid leukemia
8
runx1-runx1t1 fusion
8
fusion transcript
8
aml formation
8
runx1t1
7
aml
6

Similar Publications

Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22).

Adv Ther

January 2008

Department of Medicine, Division of Hematology/Oncology, Chang Gung Memorial Hospital-Chiayi, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.

Article Synopsis
  • * In this study of 22 patients with t(8;21)(q22;q22), factors such as higher platelet counts, lower white blood cell counts, and hematopoietic stem cell transplantation (HSCT) as postremission therapy were linked to better OS.
  • * The results suggest that treatment plans for AML patients with the t(8;21) genetic change should prioritize HSCT in postremission therapy to improve patient outcomes. *
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!